Maternal respiratory syncytial virus (RSV) vaccination and nirsevimab were associated with a reduction in RSV-associated ...

New findings provide compelling evidence for the protective benefits of maternal RSVpreF vaccination during pregnancy.

Maternal RSV vaccination and nirsevimab were associated with a reduction in RSV hospitalization rates in infants aged 0 to 7 months during the 2024-2025 RSV season.

Interim surveillance network data showed lower hospitalization rates following the availability of prevention products.

New respiratory syncytial virus (RSV) prevention products significantly reduce infant hospitalization rates, highlighting the ...

Maternal RSV vaccination and nirsevimab were associated with a reduction in hospitalization rates among infants aged 0 to 7 months.

Recent data shows that most infants are receiving RSV vaccination in the US, but rates vary by race and birth month.

New multi-center US study finds RSV co-infection in children under two is not linked to worse clinical outcomes, challenging ...

The infant mortality national rate dropped to about 5.5 infant deaths per 1,000 live births in 2024, according to provisional ...

U.S. Health and Human Services Secretary Robert F. Kennedy Jr. plans to require all new vaccines be tested against a placebo ...

A comprehensive new study reveals that respiratory syncytial virus (RSV) vaccines provide strong protection for adults aged ...

A single dose of the adult RSV vaccine RSVPreF3 OA prevented RSV–lower respiratory tract disease during 3 virus seasons in adults aged 60+.